search
Back to results

Protein Top-up Acceptability Study for Patients With Increased Protein Needs

Primary Purpose

Cancer, Neurological Injury, Respiratory Disease

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
High protein liquid
Sponsored by
Nutricia UK Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Cancer

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years of age and older.
  • Patients under the care of a Dietitian requiring oral or enteral nutritional support, with -increased protein needs.
  • To receive a minimum of 1 x 40ml HPLM daily (orally or via enteral tube) while on the study.
  • Informed consent obtained from the patient

Exclusion Criteria:

  • Total parenteral nutrition (100% of requirements).
  • Patients with major hepatic dysfunction (i.e. decompensated liver disease).
  • Patients with major renal dysfunction (i.e. requiring filtration or Stage 4/5 chronic kidney disease (CKD)).
  • Participation in other studies within 1 month prior to entry of this study.
  • Patient with severe lactose intolerance.
  • Pregnant or lactating.
  • Patient lacks capacity to consent for themselves.

Sites / Locations

  • Western Sussex Hospitals NHS Trust
  • University Hospitals Bristol

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

High protein liquid

Arm Description

A ready to use, low calorie, low volume, ready to use, high protein liquid modular (HPLM) feed for adults.

Outcomes

Primary Outcome Measures

Change in Acceptability
Acceptability of the patients existing feeding regimen (including any protein module use) will be assessed on day 1, baseline period. Acceptability with the study product will be assessed at the end of the intervention period using a standardised questionnaire completed by the patient.

Secondary Outcome Measures

Compliance
Compliance with the recommended intake of patients' currently prescribed high protein modular feed (if an existing user) and feeding regimen overall will be assessed separately at baseline. Similarly, compliance with the study product will be assessed daily throughout the intervention period and weekly when considering the patients feeding regimen overall. Compliance data will not be used in calculations for nutrient intake. For daily compliance questions, patients will be asked to record how many servings are taken compared to that recommended by their Health Care Professional (HCP). The daily amount prescribed by the HCP managing the patients care will be recorded at the start of the study and any changes to this prescription during the study will be noted. To strengthen compliance measures for the HPLM only, a count of the HPLM will be conducted on day 29 and compared to amount prescribed at baseline.
Change in Gastrointestinal tolerance
Gastrointestinal tolerance (including symptoms of diarrhoea, constipation, nausea, vomiting, abdominal pain, bloating, flatulence and burping) and information about bowel movements will be assessed during baseline (day 1), and on days 8, 15 and 29 of the intervention period using a standardised gastrointestinal tolerance questionnaire. This will be completed by the patient or their carer (using the scale: none, mild, moderate, severe symptoms)
Change in Nutrient Intake (24-hour dietary recall)
During recruitment, on a per patient and condition specific basis, the patients managing Dietitians will calculate estimated energy and protein requirements as per standard dietetic practice. Intake of all nutrition provided (including the HPLM, other enteral tube feeds, foods, drinks and oral nutritional supplements) will be recorded at baseline and at the end of the intervention period via 24 hour dietary recall. Actual intakes will subsequently be compared against Dietitians calculated estimated energy and protein requirements and percentage achievements of these requirements will also be calculated. This will include details of feeding regimens as required. Trained research staff will subsequently analyse all records utilising a nutritional software package (Nutritics Professional v3.09, Nutritics, Ireland) for macro- and micro-nutrient intakes.
Change in Physical Function (30-s Chair Stand Test)
To assess physical function, the 30-s Chair Stand Test will be completed during baseline (day 1) and at the end of the intervention period (day 29). Patients will be requested to stand up and sitting down from a chair as many times as possible within 30 seconds. This will be performed 3 times (with a 1 min rest in between sets) and an average score taken. A standard chair (with a seat height of approximately 40 cm) without armrests will be used. Initially, patients will be seated with their back in an upright position and arms folded across the chest. They will need to look straight forward and begin once ready and maintain their own preferred speed.
Change in MUST Screening
The risk of malnutrition will be assessed during baseline (day 1) and at the end of the intervention period (day 29) using the Malnutrition Universal Screening Tool (MUST). MUST is a five-step screening tool to identify adults, who are malnourished, at risk of malnutrition (undernutrition), or obese. Trials sites will receive a guide and flowchart to help quantify MUST score.
Change in Height
Height will be captured, wherever possible, using standard measures to the nearest 0.1cm.
Change in Weight
Weight will be determined to the nearest 0.1kg, using portable scales, shoeless and wearing light weight clothing.
Dietetic Goal
The dietetic goal of each patient will be recorded at baseline by the Dietitian and achievement of this goal (via yes/no responses) in the view of the Dietitian will be assessed at the end of the intervention (day 29).
Adverse events
All adverse events will be recorded, throughout the study.
Patient history
A detailed patient history will be recorded at baseline to assess previous compliance, relevant clinical issues, diagnosis, medication prescribed, details of current and previous feeding regimens, feeding history, need for protein supplementation and any other relevant clinical information related to the patient's condition or diet.

Full Information

First Posted
September 21, 2020
Last Updated
April 19, 2023
Sponsor
Nutricia UK Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT04607330
Brief Title
Protein Top-up Acceptability Study for Patients With Increased Protein Needs
Official Title
Acceptability of a Ready to Use, Low Calorie, Low Volume, High Protein Liquid for Patients With Increased Protein Needs
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
October 28, 2020 (Actual)
Primary Completion Date
May 30, 2022 (Actual)
Study Completion Date
June 28, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nutricia UK Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this prospective, single-arm intervention study is to evaluate the acceptability (compliance, gastrointestinal tolerance, and palatability) to a low calorie, low volume, ready to use, high protein liquid in patients with elevated protein needs.
Detailed Description
Increased protein needs are frequently observed in disease and can be difficult for patients to achieve where oral food intake is compromised.Where a standard ONS or enteral tube feed cannot meet the needs of patients, a modular feed can be added to the regimen, a low calorie, low volume, ready to use, high protein liquid may help meet protein needs while preventing caloric overfeeding. 40 patients will be recruited in an attempt to evaluate the acceptability (compliance, gastrointestinal tolerance, and palatability) to a low calorie, low volume, ready to use, high protein liquid in patients with elevated protein needs. After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance and dietary intake with their currently prescribed nutritional regimen, each patient will receive the high protein liquid feed daily for 28 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer, Neurological Injury, Respiratory Disease, Stroke

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Single-arm intervention study to evaluate the acceptability (compliance, gastrointestinal tolerance and palatability) of the high protein liquid feed in patients with elevated protein needs.
Masking
None (Open Label)
Allocation
N/A
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
High protein liquid
Arm Type
Experimental
Arm Description
A ready to use, low calorie, low volume, ready to use, high protein liquid modular (HPLM) feed for adults.
Intervention Type
Other
Intervention Name(s)
High protein liquid
Intervention Description
After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance, dietary intake while also capturing information related to user experience, risk of malnutrition, physical function, dietary intake, anthropometry and safety with their currently prescribed nutritional regimen, each patient will receive the high protein liquid daily for 28 days where the same measures will be replicated. The amount of the high protein liquid prescribed will always be completed by the patients' managing dietitian.
Primary Outcome Measure Information:
Title
Change in Acceptability
Description
Acceptability of the patients existing feeding regimen (including any protein module use) will be assessed on day 1, baseline period. Acceptability with the study product will be assessed at the end of the intervention period using a standardised questionnaire completed by the patient.
Time Frame
2 days (days 1 and 29)
Secondary Outcome Measure Information:
Title
Compliance
Description
Compliance with the recommended intake of patients' currently prescribed high protein modular feed (if an existing user) and feeding regimen overall will be assessed separately at baseline. Similarly, compliance with the study product will be assessed daily throughout the intervention period and weekly when considering the patients feeding regimen overall. Compliance data will not be used in calculations for nutrient intake. For daily compliance questions, patients will be asked to record how many servings are taken compared to that recommended by their Health Care Professional (HCP). The daily amount prescribed by the HCP managing the patients care will be recorded at the start of the study and any changes to this prescription during the study will be noted. To strengthen compliance measures for the HPLM only, a count of the HPLM will be conducted on day 29 and compared to amount prescribed at baseline.
Time Frame
29 days
Title
Change in Gastrointestinal tolerance
Description
Gastrointestinal tolerance (including symptoms of diarrhoea, constipation, nausea, vomiting, abdominal pain, bloating, flatulence and burping) and information about bowel movements will be assessed during baseline (day 1), and on days 8, 15 and 29 of the intervention period using a standardised gastrointestinal tolerance questionnaire. This will be completed by the patient or their carer (using the scale: none, mild, moderate, severe symptoms)
Time Frame
4 days (day 1, 8, 15 and 29)
Title
Change in Nutrient Intake (24-hour dietary recall)
Description
During recruitment, on a per patient and condition specific basis, the patients managing Dietitians will calculate estimated energy and protein requirements as per standard dietetic practice. Intake of all nutrition provided (including the HPLM, other enteral tube feeds, foods, drinks and oral nutritional supplements) will be recorded at baseline and at the end of the intervention period via 24 hour dietary recall. Actual intakes will subsequently be compared against Dietitians calculated estimated energy and protein requirements and percentage achievements of these requirements will also be calculated. This will include details of feeding regimens as required. Trained research staff will subsequently analyse all records utilising a nutritional software package (Nutritics Professional v3.09, Nutritics, Ireland) for macro- and micro-nutrient intakes.
Time Frame
2 days (day 1 and 29)
Title
Change in Physical Function (30-s Chair Stand Test)
Description
To assess physical function, the 30-s Chair Stand Test will be completed during baseline (day 1) and at the end of the intervention period (day 29). Patients will be requested to stand up and sitting down from a chair as many times as possible within 30 seconds. This will be performed 3 times (with a 1 min rest in between sets) and an average score taken. A standard chair (with a seat height of approximately 40 cm) without armrests will be used. Initially, patients will be seated with their back in an upright position and arms folded across the chest. They will need to look straight forward and begin once ready and maintain their own preferred speed.
Time Frame
2 days (day 1 and 29)
Title
Change in MUST Screening
Description
The risk of malnutrition will be assessed during baseline (day 1) and at the end of the intervention period (day 29) using the Malnutrition Universal Screening Tool (MUST). MUST is a five-step screening tool to identify adults, who are malnourished, at risk of malnutrition (undernutrition), or obese. Trials sites will receive a guide and flowchart to help quantify MUST score.
Time Frame
2 days (day 1 and 29)
Title
Change in Height
Description
Height will be captured, wherever possible, using standard measures to the nearest 0.1cm.
Time Frame
2 days (day 1 and 29)
Title
Change in Weight
Description
Weight will be determined to the nearest 0.1kg, using portable scales, shoeless and wearing light weight clothing.
Time Frame
2 days (day 1 and 29)
Title
Dietetic Goal
Description
The dietetic goal of each patient will be recorded at baseline by the Dietitian and achievement of this goal (via yes/no responses) in the view of the Dietitian will be assessed at the end of the intervention (day 29).
Time Frame
1 day (day 29)
Title
Adverse events
Description
All adverse events will be recorded, throughout the study.
Time Frame
29 days (assessed daily)
Title
Patient history
Description
A detailed patient history will be recorded at baseline to assess previous compliance, relevant clinical issues, diagnosis, medication prescribed, details of current and previous feeding regimens, feeding history, need for protein supplementation and any other relevant clinical information related to the patient's condition or diet.
Time Frame
1 day (day 1)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years of age and older. Patients under the care of a Dietitian requiring oral or enteral nutritional support, with -increased protein needs. To receive a minimum of 1 x 40ml HPLM daily (orally or via enteral tube) while on the study. Informed consent obtained from the patient Exclusion Criteria: Total parenteral nutrition (100% of requirements). Patients with major hepatic dysfunction (i.e. decompensated liver disease). Patients with major renal dysfunction (i.e. requiring filtration or Stage 4/5 chronic kidney disease (CKD)). Participation in other studies within 1 month prior to entry of this study. Patient with severe lactose intolerance. Pregnant or lactating. Patient lacks capacity to consent for themselves.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rebecca Stratton, PhD
Organizational Affiliation
Nutricia Ltd
Official's Role
Study Chair
Facility Information:
Facility Name
Western Sussex Hospitals NHS Trust
City
Worthing
State/Province
West Sussex
ZIP/Postal Code
BN11 2DH
Country
United Kingdom
Facility Name
University Hospitals Bristol
City
Bristol
ZIP/Postal Code
BS2 8HW
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Protein Top-up Acceptability Study for Patients With Increased Protein Needs

We'll reach out to this number within 24 hrs